Carcinoembryonic antigen as a marker for colorectal cancer: Is it clinically useful?

Clinical Chemistry

Volumn 47, Issue 4, 2001, Pages 624-630

  Duffy, M J ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; TUMOR MARKER;

CANCER DIAGNOSIS; CANCER STAGING; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; HUMAN; LIVER METASTASIS; PREOPERATIVE EVALUATION; PROGNOSIS; QUALITY OF LIFE; SENSITIVITY AND SPECIFICITY; SHORT SURVEY;

EID: 0035059972     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/47.4.624     Document Type: Short Survey

References (54)

1. Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques
2. Specific carcinoembryonic antigens of the human digestive system
3. Studies on the control of gene expression of the carcinoembryonic antigen family in human tissue
4. The radioimmunoassay of circulating carcinoembryonic antigen of the human digestive system
5. The structure, metabolism and function of the carcinoembryonic antigen gene family
6. Carcinoembryonic antigen gene family: Molecular biology and clinical perspectives
7. The carcinoembryonic antigen (CEA) family: Structure, suggested functions and expression in normal and malignant tissue
8. Carcinoembryonic antigen: Function in metastasis by human colorectal carcinoma
9. Carcinoembryonic antigen as a selective enhancer of cotorectal cancer metastasis
10. The use of preoperative carcinoembryonic antigen level as a prognostic indicator to complement pathological staging
11. CEA levels at recurrence and metastases: Importance for detecting secondary disease
12. Comparison of carcinoembryonic antigen in tissue and serum with grade and stage of colon cancer
13. Correlation of plasma CEA and CEA tissue staining in poorly differentiated colorectal cancer
14. The value of carcinoembryonic antigen measurement in clinical practice
15. Preoperative carcinoembryonic antigen levels in colorectal carcinoma
16. Carcinoembryonic antigen (CEA) assays in obstructive colorectal cancer
17. Multicenter tumour marker reference range study
18. A new approach in carcinoembryonic antigen-guided follow-up of large bowel carcinoma patients
19. Carcinoembryonic antigen
20. Colorectal cancer
21. CEA, AFP and other potential tumor markers
22. Carcinoembryonic antigen: Its role as a marker in the management of cancer Summary of an NIH consensus statement
23. Tumor markers of prognosis in colorectal cancer
24. The prognostic importance of tumor markers in adenocarcinemas of the gastrointestinal tract
25. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer
26. Clinical significance of the preoperative plasma carcinoembryonic antigen (CEA) level in patients with carcinoma of the large bowel
27. The preoperative carcinoembryonic antigen test in the diagnosis, staging and prognosis of celorectal cancer
28. Prognostic significance of carcinoembryonic antigen in colerectal cancer
29. Pro-operative levels of CA 242 and CEA predict outcome in colorectal cancer
30. Preoperative carcinoembryonic antigen predicts outcome in node negative colon cancer patients: A multivariate analysis of 572 patients
31. Should carcinoembryonic antigen be used in the management of patients with colorectal cancer
32. American Joint Committee on Cancer Prognostic Factors Consensus Conference: Colorectal Working Group
33. Prognostic factors in colorectal cancer
34. CEA as a prognostic factor in colorectal cancer
35. The natural history of hepatic metastases from colorectal cancer: A comparison with resective treatment
36. Current treatment for colorectal cancer metastatic to the liver
37. Pre- and postoperative carcinoembryonic antigen in hepatic resection for colorectal metastases. Predictive value and implications for adjuvant treatment based on multivariate analysis
38. Indicators for treatment strategies of colorectal liver metastases
39. Surveillance after colorectal cancer resection
40. Carcinoembryonic antigen (CEA) in diagnosis and prognosis of colorectal carcinoma
41. Role of follow-up in management of local recurrence of colorectal cancer, a prospective randomized study
42. Post surgical surveillance of colon cancer: Preliminary cost analysis of physiclan examination, CEA testing, chest X-ray and colonoscopy
43. Follow-up of colorectal cancer: A meta analysis
44. Follow-up of colorectal cancer: A meta-analysis
45. Postoperative follow-up for colorectal cancer: Who are we kidding
46. Postoperative evaluation of patients with colorectal cancer
47. Evidence for CEA utilisation following curative resection of colorectal cancer
48. Utility and cost of carcinoembryonic monitoring in colon cancer follow-up evaluation: A Markov analysis
49. CEA monitoring after surgery for colorectal cancer: When is the evidence sufficient
50. Modulation of 5-fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate
51. What can we learn from a meta-analysis of trials testing the modulation of 5-FU by leucovorin
52. Survival benefit of chemotherapy in metastatic colorectal cancer: A meta-analysis of randomized trials
53. Hepatic toxicity associated with fluorouracil plus levamisole adjuvant therapy
54. Carcinoembryonic antigen screening: Pros and cons